April 27, 2006 -- Abraxis signed a cross-licensing deal with AstraZeneca, trading co-promotion rights to cancer drug Abraxane for anesthetic/analgesic drugs; Bristol-Myers Squibb and Gilead submitted another HIV combination pill to the FDA for approval; Digene touted its HPV test as a way to protect against HPV and cervical cancer; Senesco said cancerous mice injected with a proprietary gene lived 3.5 times as long; Novartis laid off 111 Chiron employees and completed filing for FDA approval of a high blood pressure drug; Ilypsa outlicensed the Japanese rights for a dialysis drug; and Siemens will pay $1.86 billion to acquire Diagnostic Products. The Centient Biotech 200™ traded a big 49 points higher to 3765.76, a rise of 1.31%. More details...
